A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

NCT05005234 | Completed Phase 1

• 1 other identifier: GFH925X1101
• Study Type: interventional
• Target: 334
• Locations: 1 country
• Sites: 1

Brief Summary

Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925. Phase Ib: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced colorectal cancer or other tumors. Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).

Conditions

KRAS G12C

Outcome Measures

Primary Outcomes (4)

• Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); changes in laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs)

  Safety measures

  Baseline to 24 Months

• Phase Ia: Incidence of dose-limiting toxicity (DLT) events

  Safety measures

  At the end of Cycle 1（each cycle is 21 days）

• Phase Ib: ORR per RECIST 1.1

  Efficacy measures

  Continuous evaluation during treatment

• Phase II: ORR assessed by Independent Radiographic Review Committee (IRRC) according to RECIST 1.1

  Efficacy measures

  Continuous evaluation during treatment

Secondary Outcomes (5)

• Phase Ia: PK parameters of GFH925 include but are not limited to: Cmax, Tmax, AUC, t1/2, CL/F and Vd/F

  To complete 3 treatments cycles（each cycle is 21 days）

• Phase Ia: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS),Overall survival (OS)

  Continuous evaluation during treatment

• Phase Ib and Phase II: DCR, DoR, TTR, PFS per RECIST 1.1, progression-free survival rate at 6 and 12 months, overall survival rate at 12 months

  Continuous evaluation during treatment

• Phase Ib and Phase II: Incidence and severity of AEs, SAEs, AEs leading to treatment interruption, and AEs leading to treatment discontinuation of GFH925 monotherapy

  Baseline to 24 Months

• Phase Ib and Phase II: Plasma concentration (including Ctrough) after multiple dose administration in subjects

  To complete 3 treatments cycles（each cycle is 21 days）

Study Arms (1)

GFH925

EXPERIMENTAL

Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design. Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently. Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy. Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.

Drug: GFH925

Interventions

GFH925 DRUG

Administered as an oral tablet formulation

GFH925

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteer to participate in the study and sign the informed consent form.
• Aged 18 years or older at the time of signing the informed consent form.
• Subjects must have one measurable lesion (per RECIST 1.1).
• Subjects with toxic reaction caused by prior anticancer therapy need to have recovered to baseline level (except residual alopecia) or ≤ Grade 1 (neurotoxicity ≤ Grade 2 acceptable).
• Eastern Cooperative Oncology Group (ECOG) performance status score (PS) 0 \~ 1.
• Expected survival ≥ 12 weeks.
• Female subjects or male subjects of childbearing potential must take effective contraceptive measures from the time of signing the informed consent form to 30 days after the last dose of GFH925, or to 60 days after the last dose of cetuximab. Female subjects of childbearing potential should have a negative blood pregnancy test within 7 days (inclusive) prior to initiation of study treatment.
• The investigators deem the subject able to communicate well, attend regular follow-up visits, and complete the study according to the protocol.

You may not qualify if:

• Significant cardiovascular system disease.
• Subjects with unstable brain metastases diagnosed by investigators.
• Significant gastrointestinal diseases, such as intractable hiccup, nausea, vomiting, severe gastrointestinal ulcers, cirrhosis, active gastrointestinal bleeding, or other diseases that affect swallowing tablets or significantly affect oral drug absorption; subjects with severe portal hypertension caused by the presence of Budd-Chiari syndrome or portal emboli in subjects with liver cancer also need to be excluded.
• Presence of serious acute or chronic infections.
• Pregnant or lactating women.
• Known allergy to the study drug or any component of its formulation.
• Other conditions that the investigators consider inappropriate for participation in this study.

Sponsors & Collaborators

• Innovent Biologics (Suzhou) Co. Ltd.: lead

Study Sites (1)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510000, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 8, 2021
• First Posted: August 13, 2021
• Study Start: September 13, 2021
• Primary Completion: February 20, 2023
• Study Completion: December 20, 2024
• Last Updated: November 17, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)